0.76
-0.0196(-2.51%)
Currency In USD
| Previous Close | 0.78 |
| Open | 0.79 |
| Day High | 0.8 |
| Day Low | 0.7 |
| 52-Week High | 1.92 |
| 52-Week Low | 0.36 |
| Volume | 1.6M |
| Average Volume | 1.27M |
| Market Cap | 111.57M |
| PE | -2.72 |
| EPS | -0.28 |
| Moving Average 50 Days | 0.7 |
| Moving Average 200 Days | 0.91 |
| Change | -0.02 |
If you invested $1000 in Veru Inc. (VERU) 10 years ago, it would be worth $199.53 as of January 13, 2025 at a share price of $0.762. Whereas If you bought $1000 worth of Veru Inc. (VERU) shares 5 years ago, it would be worth $182.78 as of January 13, 2025 at a share price of $0.762.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
GlobeNewswire Inc.
Dec 31, 2024 1:30 PM GMT
MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
GlobeNewswire Inc.
Nov 26, 2024 1:30 PM GMT
MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
GlobeNewswire Inc.
Nov 05, 2024 1:30 PM GMT
MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute